Paget's Disease Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Paget's Disease Market is segmented By Disease Type(Paget’s Disease of the Breast, Extramammary Paget’s Disease, Paget’s Disease of the Bone (Osteitis Deformans))By Treatment Type(Surgery, Therapy, Medication)Bisphosphonate Medications,Others), By End-User(Hospitals, Specialty Clinics,Ambulatory Surgical Centers, Academic and Research Centers and Others) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030

Report Overview

Global Paget's Disease Market reached US$ YY billion in 2022 and is expected to reach US$ YY billion by 2030, growing with a high CAGR during the forecast period 2023-2030.

The global paget’s disease market witnessing significant growth and transformations in recent years, with various factors influencing its dynamics such as increasing prevalence, rising clinical trials, and others. Government investments in better treatment will continue to drive and boost the global market. The paget’s conditions are categorized based on the body parts they affect. They include Paget’s disease of the breast (nipple and areola), extramammary Paget’s disease (vulva and other areas), and Paget’s disease of the bone.

Additionally, the paget’s disease of the breast is associated with breast cancer. It is also known as mammary Paget’s disease and Paget’s disease of the nipple. Extramammary Paget’s disease is a type of carcinoma or cancer that affects epithelial tissue. It develops in certain areas with many apocrine sweat glands. These glands release fat-rich sweat with a distinct odor. Paget’s disease of the bone is also known as osteitis deformans. It’s a skeletal disorder that affects the bone’s natural remodeling process. The treatment of the paget’s disease is based on the type of the disease. 

Moreover, bisphosphonate medications is expected to hold the largest market share over the forecast period. Similarly, North America dominates the market, capturing the largest market share owing to the region’s well-established healthcare infrastructure and the presence of major players. 

Owing to the increasing prevalence of paget’s, growing awareness, rising clinical trials, increasing demand for novel therapeutics, increasing FDA approvals, and advancements in treatment options are the major factors expected to drive the global paget’s disease market over the forecast period.

Market Scope

For More Insights Request Free Sample

Market Dynamics

Increasing FDA Approvals is Expected to Drive the Growth of the Market

The increasing FDA approvals are expected to drive the growth of the paget’s disease market over the forecast period. The FDA approvals such as new drugs or medical devices, increase the trust in patients often means that patients have access to more treatment options and these FDA approvals also helps to seek alternative treatment options for better management of the disease and their associated symptoms and complications. Many generic drugs approved by the FDA helps in the treatment of paget’s disease.

For instance, on May 20, 2021, Leucadia Pharmaceuticals, a U.S. leader in generic injectables and the commercial arm of Custopharm, Inc., announced the launch of its latest FDA-approved generic, Calcitonin Salmon Injection, USP, Synthetic. The injection is therapeutically equivalent to MIACALCIN and is indicated for the early treatment of hypercalcemic emergencies when a rapid decrease in serum calcium is required. Calcitonin Salmon Injection is also used to treat osteoporosis in postmenopausal women and to treat Paget's disease.

Moreover, the process of obtaining FDA approvals requires advanced testing, research activities, and clinical trials. This encourages innovation in the field of paget’s disease as pharmaceutical and medical device companies invest in research and development to bring new and improved products to market. This innovation can stimulate market growth by addressing unmet medical needs. The increasing FDA approvals for paget’s disease can also increases the investor confidence for further developments.

Increasing Awareness is Also Expected to Drive the Growth of the Market

The increasing awareness is also expected to drive the market growth over the forecast period. The awareness about the paget’s disease, its severity, or treatment options increases, patients are more likely to seek better and advanced medical care and treatment. This increased awareness increases patient demand and can also lead to increased utilization of healthcare services and products, driving market growth.

For instance, the Paget’s Association, also known as the National Association for the Relief of Paget’s Disease, is a UK charity to focuses solely on Paget’s Disease of Bone, announced that the International Paget's Awareness Day is identified on 11th January. Every year on January 11, the Paget’s awareness day focuses on the important topic of treatment, its history, and the research changing how Paget’s disease may be managed in the future.

Additionally, awareness campaigns and programs often emphasize the importance of preventive care and early detection and management of the condition. As more people become aware of the benefits of preventive measures such as vaccinations, therapies, screenings, and lifestyle changes, they are more likely to actively engage in managing the severity of paget’s disease, resulting in a driving the market over the forecast period.

Stringent Pricing of the Treatment is Expected to Hamper the Market Growth

The stringent treatment costs are expected to hamper the market share over the forecast period. High pricing can limit access for many patients seeking better and manageable treatment, especially for people with limited insurance coverage. The high cost makes patients unaffordable for the proper treatment and management of symptoms. This can result in the hampering the market growth over the forecast period.

For instance, according to CostHelper, Inc., For patients not covered by health insurance, a mastectomy typically costs more than $15,000-$55,000, not including breast reconstruction. It is expected that the hospital charges about $15,000-$32,000 for a modified radical mastectomy. Expect to pay about $37,000 for a radical mastectomy, which involves the removal of breast tissue, nipple, underlying muscle, and lymph nodes, costs can reach $50,000 or more if there are complications. 

Furthermore, the high treatment costs especially the high cost of the surgery also hamper the research activities and clinical trials for novel therapeutics. Even among patients who initially start treatment, high costs may lead to reduced treatment adherence. This can result in suboptimal outcomes, as consistent and continuous treatment is often necessary for the best results in managing paget’s disease.

Segmentation Analysis

The global Paget’s disease market is segmented based on disease type, treatment type, end-user and region.

The Medication Segment Accounted for Approximately 37.2% of Paget’s Disease Market Share

The medications segment is expected to hold the largest market share over the forecast period. In the medications segment, biphosphonates are considered as first-line treatment for the paget’s disease treatment. Bisphosphonates are typically given by injection into a vein, but they can also be taken orally. When taken orally, bisphosphonates are generally well tolerated. There's currently no cure for Paget's disease of bone, but treatment with biphosphonates can help relieve the symptoms and reduce further complications.

Moreover, the bisphosphonates work very effectively to slow down the excessive bone remodeling characteristic of Paget's disease. By inhibiting bone resorption and reducing bone turnover, these medications help restore more normal bone structure and density in paget’s disease of bone. Bisphosphonates can alleviate common symptoms of Paget's disease, such as bone pain, deformities, and fractures. Patients often experience a significant reduction in pain and improved mobility with bisphosphonate treatment.

Geographical Share

North America Accounted for Approximately 39.1% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Well-Established Healthcare Infrastructure

North America region is expected to hold the largest market share over the forecast period owing to the strong presence of major players and well-established healthcare infrastructure. North America region is very well-known for its advanced and well-established healthcare infrastructure such as hospitals, specialty clinics, research centers, and others. This well-established healthcare infrastructure helps to manage the condition with advanced treatment options by reducing the further complications associated with paget’s disease.

Furthermore, North America especially the United States and Canada is known for its strong presence of major players such as pharmaceutical and medical device companies. The strong presence of major players actively performing clinical trials and research activities leads to novel product launches for the better treatment and management of paget’s disease. 

Market Key Players

The major global players in the Paget’s disease market include Sun Pharmaceutical Industries Ltd., Teva Canada Limited, Fresenius Kabi AG, Mylan N.V., Novartis AG, Allergan USA, Inc., DAIICHI SANKYO COMPANY, LIMITED., Viatris Inc., Ajinomoto Co., and Pfizer Inc. among others. 

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for pharmaceutical industries worldwide, including the global paget’s disease market. During the pandemic, many clinical trials, research activities, and regulatory approvals have been temporarily postponed due to the redirected focus on COVID-19 treatment and management and its related restrictions.

The onset of the pandemic in early 2020 led to widespread lockdowns and restrictions, impacting regular check-ups, appointments, and consultations worldwide related to breast paget’s disease, extramammary paget’s disease, and bone paget’s disease. Many hospitals are focused on COVID-19 cases, this reduced the paget’s disease treatment during the pandemic.

Moreover, the COVID-19 pandemic severely disrupted global supply chains, impacting the transportation of raw materials of paget’s disease related therapeutics and medical devices. Movement restrictions and border closures delayed shipments and caused drug transportation delays. Additionally, some countries faced shortages of drugs for treatment due to disruptions in their supply chain networks.

Key Developments

• On January 01, 2022, the University of Edinburgh in collaboration with the European Research Council announced that they started the observational study to identify genetic markers that are associated with the increased presence of paget’s disease of bone lesions in people with a family history of the disorder, as assessed by a radionuclide bone scan. The main aim of the present study is to try and identify genetic, epigenetic and other biomarkers for the development of paget’s disease of bone in people with a family history of the disorder in order to facilitate early diagnosis and treatment.

DataM Intelligence Opinion:

According to the DataM Intelligence, the paget’s disease market experiencing the rapid growth in recent years and is expected to grow rapidly in the coming years due to its increasing prevalence, increasing awareness, and FDA approvals for better patient outcomes. However, the high cost of the treatment is expected to hamper the market growth over the forecast period.

Further, many innovative treatment options are going to develop in the coming years by reducing the adverse effects and for effective treatment. Moreover, many clinical trials and research activities are still going on, which is expected to growth of the global paget’s disease market in the upcoming years.

Why Purchase the Report?

• To visualize the global paget’s disease market segmentation based on disease type, treatment type, end-user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of paget’s disease market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global paget’s disease market report would provide approximately 61 tables, 58 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies